Amarin | AMRN - Betriebsaufwand





Betriebsaufwand Veränderung Datum
AbbVie USD 10.27B 538M 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amarin USD 51.48M 113K 2025-12
AstraZeneca USD 12.22B 4.04B 2026-06
BioCryst Pharmaceuticals USD -553.84M 700.01M 2026-03
DBV Technologies USD 47.9M 2.2M 2026-03
GlaxoSmithKline GBP 5.8B 468M 2026-06
Halozyme Therapeutics USD 192.19M 18.88M 2026-03
Heron Therapeutics USD 40.55M 1.46M 2025-12
Ionis Pharmaceuticals USD 364M 54M 2026-03
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 599.9M 22.3M 2026-03
Novartis USD 10.2B 912M 2026-06